In a major bet on neuroscience innovation, Teva Pharmaceuticals has struck a $700 million deal to acquire Emalex Biosciences—and its promising Tourette syndrome drug, ecopipam.

 

The agreement could rise to $900 million if key commercial milestones are met, alongside additional royalties tied to global sales. The move positions Teva to expand its late-stage pipeline with a first-in-class treatment aimed at a condition with limited therapeutic options.

 

Ecopipam, a selective dopamine D1 receptor antagonist, has already delivered encouraging late-stage results. In Phase 3 trials, the drug showed statistically significant improvement in children with Tourette syndrome, clearing a major hurdle ahead of a planned regulatory filing in the second half of 2026.

 

“This is a prime example of our Pivot to Growth strategy in action, advancing focused, capital-efficient agreements that expand our late-stage innovative pipeline and commercial portfolio, while delivering on our unrelenting commitment to patients,” said Richard Francis, President and Chief Executive Officer of Teva. 

 

“There is a real unmet need in Tourette syndrome, and families deserve additional options that can help manage symptoms while minimizing side effects. With our deep neuroscience expertise, we are well-positioned to advance this first-in-class investigational compound.”

 

Unlike existing treatments that primarily target dopamine D2 receptors, ecopipam’s novel mechanism could offer a differentiated approach—potentially with fewer side effects—raising hopes among clinicians and families alike.

 

For Emalex, the deal marks the culmination of years of focused development. “This moment reflects years of focused work to advance a first-in-class therapy for patients with Tourette syndrome who need better options. I’m deeply grateful to the Emalex team for the rigor and urgency they’ve brought to this program, and to the patients, families, and investigators who made this progress possible. 

 

"Teva’s global scale and neuroscience leadership position will help ecopipam reach patients as quickly and broadly as possible, which is our goal,” said Eric Messner, Chief Executive Officer of Emalex.

 

The biotech was founded by Paragon Biosciences, which specializes in building science-driven companies. 

 

Its CEO, Jeff Aronin, underscored the strategic fit: “We built Emalex around a clear patient need and advanced ecopipam to late-stage readiness with speed and precision. At Paragon, we take companies with proven science and a clear path to patients, then choose the fastest way to reach them. Teva brings the scale and neuroscience expertise to execute globally and accelerate access for patients.”

 

The transaction, expected to close by the third quarter of 2026 pending regulatory approvals.